Section Arrow
GOVX.NASDAQ
- GeoVax Labs Inc.
Quotes are at least 15-min delayed:2026/04/14 19:25 EDT
After Hours
Last
 1.34
0 (0.00%)
Bid
1.31
Ask
1.35
High 1.35 
Low 1.31 
Volume 2.15K 
Regular Hours (Closed)
Last
 1.34
+0.06 (+4.69%)
Day High 
1.35 
Prev. Close
1.28 
1-M High
1.795 
Volume 
66.02K 
Bid
1.31
Ask
1.35
Day Low
1.28 
Open
1.2965 
1-M Low
1.1368 
Market Cap 
2.85M 
Currency 美元 
P/E -- 
%Yield -- 
10-SMA 1.28 
20-SMA 1.39 
50-SMA 1.76 
52-W High 34.75 
52-W Low 1.1368 
Exchange NASDAQ 
Valuation Estimation
EPS (Current/Estimated)
-31.75/-7.89
Enterprise Value
2.86M
Balance Sheet
Book Value Per Share
2.21
Cash Flow
Cash Flow Yield
--
Income Statement
Total Revenue
3.95M
Operating Revenue Per Share
--
Industry Comparison
Code Name   Last Change Change (%) P/E P/E Range
HOTHHoth Therapeutics0.6459+0.134+26.18%-- 
After Hours 0.65 +0.0041 +0.63%
ALLOAllogene Therapeutics2.28-0.78-25.49%-- 
After Hours 2.18 -0.1 -4.39%
VRAXVirax Biolabs Group Limited0.148-0.0184-11.06%-- 
After Hours 0.1384 -0.0096 -6.49%
CMNDClearmind Medicine Inc.0.91-0.52-36.36%-- 
After Hours 0.8501 -0.0599 -6.58%
REPLReplimune Group1.95+0.25+14.71%-- 
After Hours 1.91 -0.04 -2.05%
Industry overview quotes are at least 15 minutes delayed (Except Overnight Trading Session)
Business Description
Geovax Labs Inc is a clinical-stage biotechnology company developing human vaccines and immunotherapies against infectious diseases and solid tumor cancers using novel proprietary platforms. GeoVax's product pipeline includes ongoing humanclinical trials for a next-generation COVID-19 vaccine and a gene-directed therapy against head and neck cancers. Additional research and development programs include preventive vaccines against Monkeypox (MPox), hemorrhagic fever viruses (Ebola Zaire, Ebola Sudan, Marburg, and Lassa), and Zika virus, as well as immunotherapies for multiple solid tumors. The Company's key clinical program is GEO-CM04S1, a next-generation COVID-19 vaccine.
Information provided by: etnet
Terms and Conditions
Bank of China (Hong Kong) Limited
Disclaimer:
This information is provided by ET Net Limited ("ET Net") and/or its third party information providers (the "Sources") and is strictly for reference only. It is not intended to provide any financial or professional advice and any person should not rely upon the same as such. You should obtain relevant and specific professional advice before making any investment decision. Before making an investment decision, you should consider, with the assistance of your professional securities adviser, whether the information is appropriate in light of your particular investment needs, objectives and financial circumstances. ET Net and the Sources endeavor to ensure the accuracy and reliability of the information provided. Notwithstanding the aforesaid, ET Net, the Sources and Bank of China (Hong Kong) Limited do not guarantee or make any representation, warranty or undertaking as to the accuracy, reliability, completeness or timeliness of this information, and accept no responsibility or liability whatsoever (whether in tort or contract or otherwise) for any loss or damage howsoever arising from or in reliance upon the whole or any part of such information.